Decision Aid (DA) for Renal Patients

Status Recruiting

Clinical Trial Summary

The objective of this study is to understand how patients make decisions about treating their kidney masses, and to identify key values and preferences for treating their kidney masses. The study team will develop a decision aid (DA) using the decision-analytic model to communicate personalized benefit/harm estimates to patients and promote patient-centered treatment of renal tumors.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05387863
Study type	Interventional
Source	NYU Langone Health
Contact	Stella Kang, MD
Phone	212-263-6246
Email	Stella.kang@nyulangone.org
Status	Recruiting
Phase	N/A
Start date	September 12, 2022
Completion date	October 31, 2024

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03634540` - A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)	Phase 2
Recruiting	`NCT03175224` - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors	Phase 2
Active, not recruiting	`NCT00531284` - Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma	Phase 1/Phase 2
Recruiting	`NCT05842044` - NSAID Use After Robotic Partial Nephrectomy	Phase 2
Terminated	`NCT02669914` - MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors	Phase 2
Completed	`NCT04933604` - LPN in Patients With High-complex Renal Tumors
Withdrawn	`NCT03390413` - Robot-assisted Surgical Resection vs. Cryoablation of Localised Renal Cancer	N/A
Recruiting	`NCT05119335` - A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma	Phase 1/Phase 2
Active, not recruiting	`NCT03203473` - Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study)	Phase 2
Suspended	`NCT04115254` - Stereotactic Magnetic Resonance Guided Radiation Therapy	N/A
Enrolling by invitation	`NCT02609269` - Decipher Genomics Resource for Intelligent Discovery
Terminated	`NCT01453595` - BEZ235 in Patients With Advanced Renal Cell Carcinoma (RCC)	Phase 1/Phase 2
Completed	`NCT01444456` - Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia	N/A
Completed	`NCT02811250` - Stereotactic Radiotherapy for Renal Cancers	N/A
Completed	`NCT00398814` - Phase I Study of Perifosine + Sorafenib for Patients With Advanced Cancers	Phase 1
Completed	`NCT00399152` - Perifosine + Sunitinib Malate for Patients With Advanced Cancers	Phase 1
Completed	`NCT00458536` - Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF	Phase 1/Phase 2
Recruiting	`NCT03693014` - A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors	Phase 2
Completed	`NCT00418496` - Interleukin-2 With Sorafenib (BAY 43-9006) for Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma	Phase 1
Recruiting	`NCT06051162` - HPI Effect in Robotic Urological Surgery on AKI	N/A